

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

 **PRIMAXIN®**

imipenem and cilastatin for injection, USP

500 mg imipenem and 500 mg cilastatin (as cilastatin sodium) per vial

Sterile powder for solution, I.V. Infusion

Antibiotic

Merck Canada Inc.
16750 route Transcanadienne
Kirkland QC Canada H9H 4M7
www.merck.ca

Date of Initial Authorization:
JUL 07,1987

Date of Revision:
DEC 21, 2021

Submission Control Number: 253551

RECENT MAJOR LABEL CHANGES

4. DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations	12/2021
4. DOSAGE AND ADMINISTRATION	06/2020
7. WARNINGS AND PRECAUTIONS	06/2020

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
1.1 Pediatrics.....	5
1.2 Geriatrics.....	5
2 CONTRAINDICATIONS	5
3 SERIOUS WARNINGS AND PRECAUTIONS BOX	6
4 DOSAGE AND ADMINISTRATION	6
4.1 Dosing Considerations	6
4.2 Recommended Dose and Dosage Adjustment	8
4.3 Reconstitution.....	8
4.4 Administration	9
4.5 Missed Dose	9
5 OVERDOSAGE	10
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	10
7 WARNINGS AND PRECAUTIONS	10
7.1 Special Populations	12
7.1.1 Pregnant Women	12
7.1.2 Breastfeeding.....	12
7.1.3 Pediatrics.....	12
7.1.4 Geriatrics.....	12
8 ADVERSE REACTIONS	13

8.1	Adverse Reaction Overview	13
8.2	Clinical Trial Adverse Reactions	13
8.2.1	Clinical Trial Adverse Reactions – Pediatrics.....	15
8.3	Less Common Clinical Trial Adverse Reactions.....	15
8.3.1	Less Common Clinical Trial Adverse Reactions – Pediatrics	15
8.4	Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data.....	15
8.5	Post-Market Adverse Reactions.....	16
9	DRUG INTERACTIONS	17
9.2	Drug Interactions Overview	17
9.3	Drug-Behavioural Interactions.....	17
9.4	Drug-Drug Interactions	17
9.5	Drug-Food Interactions	18
9.6	Drug-Herb Interactions	18
9.7	Drug-Laboratory Test Interactions.....	18
10	CLINICAL PHARMACOLOGY.....	18
10.1	Mechanism of Action	18
10.2	Pharmacodynamics.....	18
10.3	Pharmacokinetics.....	18
11	STORAGE, STABILITY AND DISPOSAL.....	33
12	SPECIAL HANDLING INSTRUCTIONS.....	34
PART II: SCIENTIFIC INFORMATION		35
13	PHARMACEUTICAL INFORMATION	35
14	CLINICAL TRIALS	36
14.1	Clinical Trial by Indication	36
15	MICROBIOLOGY	36
16	NON-CLINICAL TOXICOLOGY	42
PATIENT MEDICATION INFORMATION		56

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

PRIMAXIN® is indicated for:

PRIMAXIN® may be indicated in the treatment of serious infections when caused by sensitive strains of bacteria. Where considered necessary, therapy may be initiated on the basis of clinical judgment before results of sensitivity testings are available. Continuation of therapy should be re-evaluated on the basis of bacteriological findings and of the patient's clinical condition.

Imipenem is active *in vitro* against a wide range of gram-positive and gram-negative aerobic and anaerobic bacteria, including most strains which are beta-lactamase producing. Patients have responded while under treatment with PRIMAXIN® for single or mixed infections of the following body systems, when they were associated with a number of pathogenic species and strains of the genera listed:

- Lower Respiratory Tract Infections
- Urinary Tract Infections
- Intra-Abdominal Infections
- Gynecological Infections
- Septicemia
- Endocarditis caused by *Staphylococcus aureus*
- Bone and Joint Infections
- Skin Structure Infections

PRIMAXIN® is not indicated for the treatment of meningitis.

Gram-positive Aerobes

Nocardia asteroides

Staphylococcus (excluding many strains which are methicillin resistant)

Streptococcus

[*Enterococcus faecium* (formerly *Streptococcus faecium*) is not susceptible to PRIMAXIN®.]

Gram-negative Aerobes

Acinetobacter

Citrobacter

Enterobacter

Escherichia coli

Haemophilus influenzae

Haemophilus parainfluenzae

Klebsiella

Morganella morganii

Proteus (indole positive and indole negative strains)

Providencia
Pseudomonas aeruginosa
Serratia marcescens

Gram-positive Anaerobes
Clostridium (excluding *C. difficile*)
Peptococcus
Peptostreptococcus

Gram-negative Anaerobes
Bacteroides fragilis
Bacteroides (non fragilis)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of PRIMAXIN® and other antibacterial drugs, PRIMAXIN® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

1.1 Pediatrics

Pediatrics (<3 months): Based on the data submitted and reviewed by Health Canada, the safety and efficacy in pediatric patients <3 months has not been established. (see [4.2 Recommended Dose and Dosage Adjustment](#), [7.1.3 Pediatrics](#) and [8.2.1 Clinical Trial Adverse Reactions – Pediatrics](#))

Pediatrics (3 months – 18 years): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of PRIMAXIN® in pediatric patients has been established. (see [4.2 Recommended Dose and Dosage Adjustment](#), [7.1.3 Pediatrics](#) and [8.2.1 Clinical Trial Adverse Reactions – Pediatrics](#))

1.2 Geriatrics

Geriatrics (≥65 years old): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. (see [7.1.4 Geriatrics](#))

2 CONTRAINDICATIONS

PRIMAXIN® IS CONTRAINDICATED IN PATIENTS WHO ARE HYPERSENSITIVE TO THIS DRUG OR TO ANY INGREDIENT IN THE FORMULATION, INCLUDING ANY NON-MEDICINAL INGREDIENT, OR COMPONENT OF THE CONTAINER. FOR A COMPLETE LISTING, SEE 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Not applicable.

4 DOSAGE AND ADMINISTRATION

The dosage recommendations for PRIMAXIN® (imipenem and cilastatin sodium) represent the quantity of imipenem to be administered by I.V. infusion only. An equivalent amount of cilastatin is also present in the solution.

The dosage of PRIMAXIN® should be determined by the severity of the infection, renal function, the antibiotic susceptibility of the causative organism(s) and the condition of the patient.

The median duration of treatment with PRIMAXIN® in clinical trials for infections of the various body systems ranged from 6 to 10 days except for endocarditis and bone and joint infections for which the median duration of treatment was 4 weeks.

4.1 Dosing Considerations

- **Dosage in Adults**

- The dosage of PRIMAXIN® in adult patients should be based on suspected or confirmed pathogen susceptibility as shown in Table 1 below.
- These doses should be used for patients with creatinine clearance (CrCl) of greater than or equal to 90 mL/min. A reduction in dose must be made for patients with creatinine clearance less than 90 mL/min as shown in **Table 2**.
- It is recommended that the maximum total daily dosage not exceed 4 g/day.

Table 1: Dosage of PRIMAXIN® in Adult Patients with Creatinine Clearance Greater than or Equal to 90 mL/min

Suspected or Proven Pathogen Susceptibility	Dosage of PRIMAXIN®
If the infection is suspected or proven to be due to bacterial species or isolate that is susceptible (S) (CLSI) (see 15 MICROBIOLOGY)	500 mg every 6 hours
	OR 1000 mg every 8 hours
If the infection is suspected or proven to be due to bacterial species or isolate that is intermediate (I) (CLSI) (see 15 MICROBIOLOGY)	1000 mg every 6 hours

- **Dosage in Adult Patients with Renal Impairment**

Patients with creatinine clearance less than 90 mL/min require dosage reduction of PRIMAXIN® as indicated in Table 2. The serum creatinine should represent a steady state of renal function. Use the Cockcroft-Gault method described below to calculate the creatinine clearance:

Males: $\frac{(\text{weight in kg}) \times (140 - \text{age in years})}{(72) \times \text{serum creatinine (mg/100 mL)}}$

Females: $(0.85) \times (\text{value calculated for males})$

Table 2: Dosage of PRIMAXIN® for Adult Patients in Various Renal Function Groups Based on Estimated Creatinine Clearance

	Creatinine clearance (mL/min)			
	Greater than or equal to 90	Less than 90 to greater than or equal to 60	Less than 60 to greater than or equal to 30	Less than 30 to greater than or equal to 15
Dosage of PRIMAXIN® *,† If the infection is suspected or proven to be due to bacterial species-or isolate that is susceptible (S) (CLSI) (see 15 MICROBIOLOGY)	500 mg every 6 hours	400 mg every 6 hours	300 mg every 6 hours	200 mg every 6 hours
	OR			
	1000 mg every 8 hours	500 mg every 6 hours	500 mg every 8 hours	500 mg every 12 hours
Dosage of PRIMAXIN® *,† If the infection is suspected or proven to be due to bacterial species or isolate that is intermediate (I) (CLSI) (see 15 MICROBIOLOGY)	1000 mg every 6 hours	750 mg every 8 hours	500 mg every 6 hours	500 mg every 12 hours

* Administer doses less than or equal to 500 mg by intravenous infusion over 20 to 30 minutes.

† Administer doses greater than 500 mg by intravenous infusion over 40 to 60 minutes. In patients who develop nausea during the infusion, the rate of infusion may be slowed.

In patients with creatinine clearances of less than 30 to greater than or equal to 15 mL/min, there may be an increased risk of seizures (see [7 WARNINGS AND PRECAUTIONS](#)). Patients with creatinine clearance less than 15 mL/min should not receive PRIMAXIN® unless hemodialysis is instituted within 48 hours. There is inadequate information to recommend usage of PRIMAXIN® for patients undergoing peritoneal dialysis.

- **Dosage in Hemodialysis Patients**

When treating patients with creatinine clearances of less than 15 mL/min who are undergoing hemodialysis, use the dosage recommendations for patients with creatinine clearances of less than 30 to greater than or equal to 15 mL/min in Table 2 above (see **Dosage in Adult Patients with Renal Impairment**). Both imipenem and cilastatin are cleared from the circulation during hemodialysis. The patient should receive PRIMAXIN® after hemodialysis and at intervals timed from the end of that

hemodialysis session. Dialysis patients, especially those with background CNS disease, should be carefully monitored; for patients on hemodialysis, PRIMAXIN® is recommended only when the benefit outweighs the potential risk of seizures. (see **Dosage in Adult Patients with Renal Impairment**).

4.2 Recommended Dose and Dosage Adjustment

- **Pediatric Patients (3 months – 18 years)**

PRIMAXIN® is not recommended in pediatric patients with CNS infections because of the risk of seizures (see [7.1.3 Pediatrics](#) and [8.2 Clinical Trial Adverse Reactions](#)).

PRIMAXIN® is not recommended in pediatric patients <30 kg with renal impairment, as no data are available (see [7 WARNINGS AND PRECAUTIONS](#) and [7.1.3 Pediatrics](#)).

Based on studies in adults, the maximum total daily dose in pediatric patients should not exceed 4 g/day (see **Dosage in Adults**).

The recommended dosage for pediatric patients with non-CNS infections is shown in Table 3 below:

Table 3: Recommended PRIMAXIN® Dosage in Pediatric Patients for Non-CNS Infections

Age	Dose (mg/kg) *,†	Frequency (hours)
Greater than or equal to 3 Months of Age	15-25 mg/kg	Every 6 hours

* Doses less than or equal to 500 mg should be given by intravenous infusion over 20 to 30 minutes.

† Doses greater than 500 mg should be given by intravenous infusion over 40 to 60 minutes.

Recommend that the maximum total daily dosage not exceed 4 g/day.

4.3 Reconstitution

Parenteral Products:

Preparation of PRIMAXIN® Solution for IV Administration

PRIMAXIN® is supplied as a dry powder in a single-dose vial that must be reconstituted and further diluted using aseptic technique prior to IV infusion as outlined below.

- To prepare the infusion solution, contents of the vial must be reconstituted by adding approximately 10 mL of the appropriate diluent to the vial (see [11 STORAGE, STABILITY AND DISPOSAL](#)).
- Withdraw 20 mL (10 mL times 2) of diluent from the appropriate infusion bag and constitute the vial with 10 mL of the diluent. The reconstituted suspension must not be administered by direct IV infusion.
- After reconstitution, shake vial well and transfer resulting suspension into the remaining 80 mL of the infusion bag.

- Add the additional 10 mL of infusion solution to the vial and shake well to ensure complete transfer of vial contents; repeat transfer of the resulting suspension to the infusion solution before administering. Agitate the resulting mixture until clear.
- For patients with renal insufficiency, a reduced dose of PRIMAXIN® will be administered according to the patient's CrCl, as determined from Table 2. Prepare 100 mL of infusion solution as directed above. Select the volume (mL) of the final infusion solution needed for the appropriate dose of PRIMAXIN® as shown in Table 4.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard if discoloration or visible particles are observed.

Table 4: Preparation of PRIMAXIN® Doses

Creatinine Clearance (mL/min)	Dosage of PRIMAXIN® (imipenem/cilastatin (mg))	Volume (mL) of Solution to be Removed and Discarded from Preparation	Volume (mL) of Final Infusion Solution Needed for Dosage
Greater than or equal to 90	500/500	N/A	100
Less than 90 to greater than or equal to 60	400/400	20	80
Less than 60 to greater than or equal to 30	300/300	40	60
Less than 30 to greater than or equal to 15	200/200	60	40

4.4 Administration

CAUTION: CONTENTS OF VIALS NOT FOR DIRECT INFUSION.

Each reconstituted 500 mg dose should be given by intravenous infusion over 20 to 30 minutes. Each 1000 mg dose should be infused over 40 to 60 minutes. In patients who develop nausea during the infusion, the rate of infusion may be slowed (see **Dosage in Adults**).

- Administer 500 mg by intravenous infusion over 20 to 30 minutes.
- Administer 1000 mg by intravenous infusion over 40 to 60 minutes.
- In patients who develop nausea during the infusion, the rate of infusion may be slowed.

4.5 Missed Dose

The injection schedule will be set by the doctor, who will monitor the response and condition to

determine what treatment is needed.

5 OVERDOSAGE

In case of overdosage, discontinue PRIMAXIN[®], treat symptomatically and institute supportive measures as required. Imipenem-cilastatin sodium is cleared by hemodialysis. Usefulness of this procedure in the overdosage setting is questionable.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 5 – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Intravenous	500 mg imipenem and 500 mg cilastatin (as cilastatin sodium) per vial	Sodium bicarbonate

7 WARNINGS AND PRECAUTIONS

GENERAL

SEVERE AND OCCASIONALLY FATAL (ANAPHYLACTIC) REACTIONS HAVE BEEN REPORTED WITH MOST BETA-LACTAM ANTIBIOTICS. THESE REACTIONS ARE MORE APT TO OCCUR IN PERSONS WITH A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS.

THERE IS SOME CLINICAL AND LABORATORY EVIDENCE OF PARTIAL CROSS-ALLERGENICITY BETWEEN PRIMAXIN[®] AND THE OTHER BETA-LACTAM ANTIBIOTICS. BEFORE INITIATING THERAPY WITH PRIMAXIN[®], CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTION TO BETA-LACTAM ANTIBIOTICS, PENICILLINS AND CEPHALOSPORINS AND OTHER ALLERGENS.

IF AN ALLERGIC REACTION TO PRIMAXIN[®] OCCURS, THE DRUG SHOULD BE DISCONTINUED AND APPROPRIATE MEASURES UNDERTAKEN. SERIOUS ANAPHYLACTIC REACTIONS REQUIRE IMMEDIATE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES.

CNS adverse experiences such as myoclonic activity, confusional states, or seizures have been reported with PRIMAXIN[®] especially when recommended dosages based on renal function and body weight were exceeded. These experiences have occurred most commonly in patients with CNS disorders (e.g., brain lesions or history of seizures) and/or who have compromised renal function. However, there were rare reports in which there was no recognized or documented underlying CNS disorder.

When recommended doses were exceeded, adult patients with creatinine clearances of ≤ 20 mL/min/1.73 m², whether or not undergoing hemodialysis, had a higher risk of seizure activity than those without impairment of renal function. Close adherence to recommended dosage schedules is

urged especially in patients with known factors that predispose to seizures (see [4 DOSAGE AND ADMINISTRATION](#)).

Patients with creatinine clearances of ≤ 5 mL/min/1.73 m² should not receive PRIMAXIN[®] unless hemodialysis is instituted within 48 hours.

For patients on hemodialysis, PRIMAXIN[®] is recommended only when the benefit outweighs the potential risk of seizures.

Anticonvulsant therapy should be continued in patients with a known seizure disorder. If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically and placed on anticonvulsant therapy if not already instituted. If CNS symptoms continue, the dosage of PRIMAXIN[®] should be decreased or discontinued (see [9 DRUG INTERACTIONS / Drug-Drug Interactions](#) DRUG INTERACTIONS).

Severe Cutaneous Adverse Reactions

Severe cutaneous adverse reactions (SCAR) such as acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) have been reported in association with beta-lactam treatment. When SCAR is suspected, PRIMAXIN[®] should be discontinued and appropriate therapy and/or measures should be taken.

Neurologic

Seizures and other CNS adverse experiences, such as confusional states and myoclonic activity, have been reported during treatment with PRIMAXIN (see [8 ADVERSE REACTIONS](#)).

Case reports in the literature have shown that co-administration of carbapenems, including imipenem, to patients receiving valproic acid or divalproex sodium results in a reduction in serum valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction. In some cases of co-administration of imipenem with valproic acid, breakthrough seizures have occurred. Increasing the dose of valproic acid or divalproex sodium may not be sufficient to overcome this interaction. The concomitant use of imipenem and valproic acid/divalproex sodium is generally not recommended. Anti-bacterials other than carbapenems should be considered to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium. If administration of PRIMAXIN[®] is necessary, supplemental anti-convulsant therapy should be considered (see [9 DRUG INTERACTIONS / Drug-Drug Interactions](#)).

Gastrointestinal

Clostridioides difficile-associated disease

Clostridioides difficile-associated disease (CDAD) has been reported with the use of many antibacterial agents, including PRIMAXIN[®]. CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symptoms of colitis, pseudomembranous colitis, toxic megacolon, or perforation of colon subsequent to the administration of any antibacterial agent. CDAD has been reported to occur over 2 months after the administration of antibacterial agents.

Treatment with antibacterial agents may alter the normal flora of the colon and may permit overgrowth of *Clostridioides difficile*. *Clostridioides difficile* produces toxins A and B, which contribute to the

development of CDAD. CDAD may cause significant morbidity and mortality. CDAD can be refractory to antimicrobial therapy.

If the diagnosis of CDAD is suspected or confirmed, appropriate therapeutic measures should be initiated. Mild cases of CDAD usually respond to discontinuation of antibacterial agents not directed against *Clostridioides difficile*. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial agent clinically effective against *Clostridioides difficile*. Surgical evaluation should be instituted as clinically indicated, as surgical intervention may be required in certain severe case (see [8 ADVERSE REACTIONS](#)).

Susceptibility/Resistance

Development of Drug Resistant Bacteria

Prescribing PRIMAXIN[®] in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and risks the development of drug-resistant bacteria. Repeated evaluation of the patient's condition is essential. If superinfection occurs during therapy, appropriate measures should be taken.

Renal

Dosage in patients with impaired renal function is based on the severity of infection but the maximum daily dose varies with the degree of renal functional impairment (see [4 DOSAGE AND ADMINISTRATION](#)).

7.1 Special Populations

7.1.1 Pregnant Women

The use of PRIMAXIN[®] in pregnant women has not been studied. PRIMAXIN[®] should be used during pregnancy only if the potential benefit justifies the potential risk to the mother and fetus.

Reproduction studies with bolus I.V. doses suggest an apparent intolerance to PRIMAXIN[®] (including emesis, inappetence, body weight loss, diarrhea and death) at doses equivalent to the average human dose in pregnant rabbits and cynomolgus monkeys that is not seen in non-pregnant animals in these or other species. In other studies, PRIMAXIN[®] was well tolerated in equivalent or higher doses (up to 11 times the average human dose) in pregnant rats and mice (see [16 NON-CLINICAL TOXICOLOGY](#)).

7.1.2 Breastfeeding

Imipenem has been detected in human milk. If the use of PRIMAXIN[®] is deemed essential, the patient should not breastfeed.

7.1.3 Pediatrics

Pediatric Patients (<3 months of age): Efficacy and tolerability in infants under the age of 3 months have not yet been established; therefore, PRIMAXIN[®] is not recommended in the pediatric age group below the age of 3 months. Clinical data are insufficient to recommend the use of PRIMAXIN[®] for pediatric patients with impaired renal function (serum creatinine >2mg/dL) (see [4.2 Recommended Dose and Dosage Adjustment](#)).

7.1.4 Geriatrics

Geriatric (≥65 years old): No dosage adjustment is required solely on the basis of age (see, DOSAGE AND ADMINISTRATION, Geriatric). This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

Adults

. The following adverse reactions were reported in 1,723 patients treated in clinical trials. Many of these patients were severely ill and had multiple background diseases and physiological impairments, making it difficult to determine causal relationship of adverse experiences to therapy with PRIMAXIN®.

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

The most frequently reported systemic adverse clinical reactions that were reported were nausea, diarrhea, vomiting, rash, fever, hypotension, seizures, dizziness pruritus, urticaria and somnolence.

The following side effects have been reported during clinical studies and in post-marketing experience.

Local Adverse Reactions

Adverse local clinical reactions that were reported as possibly, probably or definitely related to therapy with PRIMAXIN® were:

	Incidence (%)
Phlebitis/thrombophlebitis	3.1
Pain at the injection site	0.7
Erythema at the injection site	0.4
Vein induration	0.2
Infused vein infection	0.1

Systemic Adverse Reactions

Adverse clinical reactions that were reported as possibly, probably or definitely related to PRIMAXIN® were:

	Incidence (%)
Gastrointestinal	
Nausea	2.0
Diarrhea	1.8
Vomiting	1.5
Tongue papillar hypertrophy	<0.2
Pseudomembranous colitis (see 7 WARNINGS AND PRECAUTIONS)	0.1
Hemorrhagic colitis	<0.1
Gastroenteritis	<0.1
Abdominal pain	<0.1
Glossitis	<0.1
Heartburn	<0.1
Pharyngeal pain	<0.1
Increased salivation	<0.1
CNS	
Fever	0.5
Dizziness	0.3
Seizures (see 7 WARNINGS AND PRECAUTIONS)	0.4
Somnolence	0.2
Confusion	<0.2
Myoclonus	0.1
Vertigo	0.1
Headache	0.1
Encephalopathy	<0.1
Paresthesia	<0.1
Special Senses	
Transient hearing loss in patients with impaired hearing	<0.1
Tinnitus	<0.1
Respiratory	
Dyspnea	0.1
Hyperventilation	<0.1
Thoracic spine pain	<0.1
Cardiovascular	
Hypotension	0.4
Palpitations	0.1
Tachycardia	<0.1
Renal	
Oliguria/anuria	<0.1
Polyuria	<0.1
Skin	
Rash	0.9

	Incidence (%)
Pruritus	0.3
Urticaria	0.2
Skin texture changes	0.1
Candidiasis	0.1
Erythema multiforme	<0.1
Facial edema	<0.1
Flushing	<0.1
Cyanosis	<0.1
Hyperhidrosis	<0.1
Pruritus vulvae	<0.1
Body as a whole	
Polyarthralgia	<0.1
Asthenia/weakness	<0.1

8.2.1 Clinical Trial Adverse Reactions – Pediatrics

Pediatrics (≥ 3 months of age):

In studies of 178 pediatric patients, the most common clinical adverse experiences (>1%) without regard to Drug relationship were as follows:

Digestive System: diarrhea (3.9%), gastroenteritis (1.1%), vomiting (1.1%)

Skin: rash (2.2%), irritation at IV site (1.1%)

Urogenital System: urine discoloration (1.1%)

Cardiovascular System: phlebitis (2.2%)

In this age group abnormal laboratory values for hemoglobin, hematocrit, neutrophils, eosinophils, platelet count, urine protein, serum creatinine, BUN, AST and ALT occurred during therapy*.

*pre-therapy values were normal

8.3 Less Common Clinical Trial Adverse Reactions

Not Applicable.

8.3.1 Less Common Clinical Trial Adverse Reactions – Pediatrics

Not Applicable.

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

Clinical Trial Findings

Adverse laboratory changes, without regard to drug relationship, that were reported during clinical trials were:

Hepatic: Increased ALT (SGPT), AST (SGOT), alkaline phosphatase, bilirubin and LDH.

Hemic: Increased eosinophils, positive Coombs' test, leukopenia (decreased WBC), neutropenia (decreased neutrophils), increased WBC, increased platelets, thrombocytopenia (decreased platelets), decreased hemoglobin and hematocrit, increased monocytes, abnormal prothrombin time, increased lymphocytes, increased basophils.

Electrolytes: Decreased serum sodium, increased potassium, increased chloride.

Renal: Increased blood urine nitrogen (BUN), serum creatinine.

Urinalysis: Presence of urine protein, urine red blood cells, urine white blood cells, urine casts, urine bilirubin, and urine urobilinogen.

8.5 Post-Market Adverse Reactions

The following reactions have been reported since the drug was marketed, but occurred under circumstances where a causal relationship could not be established. However, in these rarely reported events, that possibility cannot be excluded. Therefore, these observations are listed to serve as alerting information to healthcare professionals:

- Acute renal failure. The role of PRIMAXIN® in changes in renal function is difficult to assess, since factors predisposing to pre-renal azotemia or to impaired renal function usually have been present.
- Anaphylactic reactions
- Angioneurotic edema
- Agitation
- Agranulocytosis
- Bone marrow depression
- Chest discomfort
- Drug fever
- Dyskinesia
- Exfoliative dermatitis
- Hallucinations
- Hearing loss
- Hemolytic anemia
- Hepatic failure
- Hepatitis (including Fulminant hepatitis)
- Jaundice
- Pancytopenia
- Psychic disturbances
- Staining of teeth and/or tongue
- Stevens-Johnson syndrome
- Taste perversion
- Toxic epidermal necrolysis
- Tremor
- Urine discoloration

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

Not applicable.

9.3 Drug-Behavioural Interactions

Not applicable.

9.4 Drug-Drug Interactions

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Table 6 - Established or Potential Drug-Drug Interactions

[Proper/Common name]	Source of Evidence	Effect	Clinical comment
Ganciclovir	C	imipenem	Generalized seizures have been reported in patients who received ganciclovir and PRIMAXIN®. These drugs should not be used concomitantly unless the potential benefits outweigh the risks.
Valproic acid or divalproex sodium	C	Carbapenems, including imipenem	Reduction of serum valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction. In some cases of co-administration of imipenem with valproic acid, breakthrough seizures have occurred. The mechanism of this interaction is unknown. See 7 WARNINGS AND PRECAUTIONS
Probenecid	CT	imipenem	Concomitant administration of PRIMAXIN® and probenecid results in increases in plasma levels and plasma half-life of imipenem. It is not recommended that probenecid be given with PRIMAXIN®

Legend: C = Case Study; CT = Clinical Trial; T = Theoretical

9.5 Drug-Food Interactions

Interactions with food have not been established.

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Imipenem exerts a bactericidal action by inhibiting cell wall synthesis in aerobic and anaerobic gram-positive and gram-negative bacteria.

PRIMAXIN® (imipenem and cilastatin sodium for injection, USP) consists of two components: (1) imipenem, a derivative of thienamycin, a carbapenem antibiotic; and (2) cilastatin sodium, a specific inhibitor of dehydropeptidase-I a renal enzyme which metabolizes and inactivates imipenem. Cilastatin blocks the metabolism of imipenem in the kidney, so that concomitant administration of imipenem and cilastatin allows antibacterial levels of imipenem to be attained in the urine.

Inhibition of cell-wall synthesis is achieved in gram-negative bacteria by the binding of imipenem to penicillin binding proteins (PBPs). In the case of *Escherichia coli* and selected strains of *Pseudomonas aeruginosa*, imipenem has been shown to have highest affinity for PBP-2, PBP-1a and PBP-1b, with lower activity against PBP-3. The preferential binding of imipenem on PBP-2 and PBP-1b leads to direct conversion of the individual cell to a spheroplast resulting in rapid lysis and cell death without filament formation. When imipenem is removed prior to complete killing of gram-negative-----species, the remaining viable cells show a measurable lag, termed a "post-antibiotic effect" (PAE), prior to resumption of new growth.

10.2 Pharmacodynamics

See [9.4 Drug-Drug Interactions](#), [10.1 Mechanism of Action](#), [10.3 Pharmacokinetics](#) and [15 MICROBIOLOGY](#).

10.3 Pharmacokinetics

Absorption

PRIMAXIN® was administered via intravenous infusion over 20 minutes at a single dose of 250/250 mg to 4 male subjects (mean age: 31.5 ± 0.6 years), at a single dose of 500/500 mg to 20 male subjects (mean age: 26.8 ± 4.1 years), and at a single dose of 1000/1000 mg to 8 male subjects (mean age: 24.8 ± 3.7 years). Peak plasma levels of imipenem and of cilastatin were measured at the end of a 20 minute infusion, and are presented in Table 6. Plasma levels of imipenem antimicrobial activity are proportional to the dose and decline to below 1 mcg/mL or less in 4 to 6 hours.

TABLE 7: RANGE OF PEAK PLASMA LEVELS OF IMIPENEM AND CILASTATIN FOLLOWING A 20 MINUTE I.V. INFUSION OF PRIMAXIN®

	250/250 mg	500/500 mg	1000/1000 mg
Imipenem (mcg/mL)	12 - 20	21 - 58	41 - 83
Cilastatin (mcg/mL)	21 - 26	21 - 55	56 - 88

PRIMAXIN® was administered via the intravenous route, over a 30 minutes period, every 6 hours, for a period of 10 days, at a dose of 1000/1000 mg, to a group of six male volunteers (mean age 28.2 ± 5.0).

Mean plasma and urine concentrations for imipenem are given in Figure 1 and Table 7 respectively.




FIGURE 1: MEAN IMIPENEM PLASMA CONCENTRATION PROFILES WHEN PRIMAXIN® IS ADMINISTERED AT A DOSE OF 1000/1000 mg, BY I.V. INFUSION, OVER 30 min (every 6 h) (n = 6)

TABLE 8: MEAN IMIPENEM URINE CONCENTRATIONS (mcg/mL ± S.D.) WHEN PRIMAXIN® IS ADMINISTERED AT A DOSE OF 1000/1000 mg BY I.V. INFUSION, OVER 30 min (every 6 h)

	0 - 2 h	2 - 4 h	4 - 6 h
Day 1	886.6 (±511.3)	562.8 (±269.3)	175.8 (±167.9)
Day 5	1026.1 (±503.9)	1185.8 (±932.4)	156.1 (± 93.77)
Day 10	1389.5 (±616.4)	891.5 (±430.6)	159.9 (± 49.1)

The pharmacokinetic parameters for imipenem and cilastatin, when PRIMAXIN® was administered at a dose of 1000/1000 mg, are summarized in Table 8.

TABLE 9: PHARMACOKINETIC PARAMETERS OF IMIPENEM AND CILASTATIN WHEN PRIMAXIN® IS ADMINISTERED AT A DOSE OF 1000/1000 mg BY I.V. INFUSION OVER 30 min (N = 6)

Time (days)	Volume of Distribution (L)	Area under the Plasma Concentration Time Curve Between 0 and 6 h (mcg.h/mL)	Plasma Half-Lives (min)*	Dose Recovered in urine through 6 h (mg)	Cumulative Renal Clearance (mL/min)	Plasma Clearance (mL/min)
IMIPENEM						
Day 1	13.6 (±3.7)	73.3 (±10.4)	59.6	540.2 (±54.1)	126.5 (±29.9)	227.7 (±30.9)
Day 5	11.4 (±3.8)	74.5 (±10.9)	61.3	651.8 (±148.1)	139.9 (±27.4)	227.8 (±36.1)
Day 10	10.9 (±1.6)	79.7 (±7.1)	59.4	626.5 (±77.2)	131.3 (±21.0)	210.4 (±18.3)
CILASTATIN						

Day 1	10.3 (±3.9)	82.1 (±19.3)	57.5	698.6 (±33.9)	142.7 (±33.6)	208.9 (±43.0)
Day 5	9.5 (±1.4)	73.0 (±16.1)	50.7	ND	ND	236.5 (±44.9)
Day 10	9.7 (±2.1)	77.4 (±15.1)	50.8	ND	ND	221.6 (±38.6)

*Harmonic means

Metabolism: Imipenem, when administered alone, is metabolized in the kidneys by dehydropeptidase-I and therefore achieves relatively low levels in urine.

Cilastatin sodium is a specific inhibitor of this enzyme and it prevents renal metabolism of imipenem.

Elimination:

When imipenem and cilastatin sodium are given concomitantly, approximately 70% of the administered imipenem and cilastatin sodium are recovered unchanged in the urine within 10 hours of administration, after which no further urinary excretion is detectable. Urine concentrations of imipenem in excess of 10 mcg/mL can be maintained for up to 8 hours with PRIMAXIN® at the 500 mg dose.

The remainder of the administered dose of imipenem is recovered in the urine as antibacterially inactive metabolites and fecal elimination of imipenem is essentially nil.

Approximately 10% of the cilastatin sodium administered is found as the N-acetyl metabolite, which has inhibitory activity against dehydropeptidase comparable to that of the parent drug. Activity of dehydropeptidase-I in the kidney returns to normal levels within approximately 8-12 hours after the elimination of cilastatin from the bloodstream.

No accumulation of imipenem and cilastatin in plasma is observed with regimens of PRIMAXIN® administered at therapeutic doses, in patients with normal renal function.

Distribution:

Serum Protein Binding: At serum concentration of 25 mg/L, the human serum protein binding of imipenem is 20%. Cilastatin sodium binding to protein was found to be approximately 35% in the human serum.

Tissue Concentrations: Concurrent imipenem concentrations in serum, tissues and body fluids are given in Table 9.

TABLE 10: IMIPENEM CONCENTRATIONS IN HUMAN TISSUES AFTER ADMINISTRATION BY I.V. INFUSION

Tissue/Fluid	Dose of Imipenem (mg)	Sampling time (min after dose)	No. of Specimens	Concentration	
				Tissue/Fluid (mg/L or mg/kg)	Serum (mg/L)
Bile ⁽¹⁾	500	20	9	MEAN MAX (RANGE)	
		180		12.5 (5.25 - 20.3)	-
	1000	20	8	25.0 (10.7 - 51.28)	
		180		(1.45 - 4.12)	-
Cerebrospinal ⁽²⁾	1000	60	4	MEAN ± S.D.	
		90		2.0 (±1.3)	MEAN ± S.D.(n=4)
		120		1.5 (±0.1)	22.3 (±14.6)
				2.7 (±2.3)	8.0 (± 1.6)
					13.9 (±14.4)
Saliva ⁽³⁾	1000	15 - 60	10	MEAN(RANGE)	
Sputum ⁽³⁾	1000	15 - 120	7	0.38 (0.3 - 0.6)	
Bone ⁽³⁾	1000	30 - 120	10	4.4 (2.1 - 10.4)	
Wound Drainage ⁽³⁾	1000	15 - 120	9	2.6 (0.4 - 5.4)	
Gastric Fluid ⁽³⁾	1000	15 - 90	6	7.2 (1.7 - 22.6)	
				0.9 (0.4 - 1.7)	
Heart Valves ⁽⁴⁾	1000	0 - 60	3	MEAN ± S.E.	
Fat ⁽⁴⁾	1000	0 - 60	10	3.3 (±0.7)	
Muscle ⁽⁴⁾	1000	0 - 60	10	0.8 (±0.3)	
				2.5 (±0.7)	
Myometrium ⁽⁴⁾	500	60 - 120	5	MEAN ± S.E.	
Endometrium ⁽⁴⁾	500	60 - 120	5	2.5 (±0.3)	
Salpinges ⁽⁴⁾	500	60 - 120	2	1.6 (±0.3)	
				1.4 (±0.1)	

** 15 min post infusion

- (1) Mayer M, Tophoff C, Opperkuch W. Bile levels of imipenem following different dose regimens. *Int J Clin Pharmacol Res* 1985; V(5):325-9.
- (2) Modal J, Vittecoq D, Decazes JM, Meulemans A. Penetration of imipenem and cilastatin into cerebrospinal fluid of patients with bacterial meningitis. *J Antimicrob Chemother* 1985;16: 751-5.
- (3) MacGregor RR, Gibson GA, Bland JA. Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment of serious infections. *Antimicrob Agents Chemother* 1986;29(2):188-92.
- (4) Kümmel A, Schlosser V, Petersen E, Daschner FD. Pharmacokinetics of imipenem-cilastatin in serum and tissue. *Eur J Clin Microbiol* 1985;4(6):609-10.

Special Populations and Conditions

- **Pediatrics** : The pharmacokinetic results from two pediatric single dose studies are summarized in Table 10.

TABLE 11: MEAN VALUES OF PHARMACOKINETIC PARAMETERS OF IMIPENEM/CILASTATIN IN CHILDREN AFTER A SINGLE DOSE OF PRIMAXIN® (10/10 or 25/25 mg/kg) ADMINISTERED I.V. OVER 10-20 min

AGE RANGE (years)	No. PATIENTS	[AUC*] (mcg.h/mL/mg)	PLASMA CLEARANCE (mL/min/kg)	VOLUME OF DISTRIBUTION (L/kg)	T _{1/2} ⁺ (min)	URINE RECOVERY (% OF DOSE)
2-12	20 [†]	0.20 / 0.29 (n=9)/(n=3)	5.33 / 4.20 (n=9)/(n=3)	0.25 / 0.17 (n=9)/(n=3)	55.8 / 36.5 (n=20)/(n=10)	61.0 / 79.0 (n=7)/(n=5)
2-9	9	0.18 / 0.20	5.40 / 4.90	0.22 / 0.15	53.7 / 37.9	41.0 / 66.0

* AUC expressed per milligram of drug administered.

⁺ Harmonic means.

[†] Number of patients from which pharmacokinetic parameters were calculated are given in between parentheses.

The pharmacokinetic results from two pediatric studies in which PRIMAXIN® was administered in multiple doses are summarized in Table 11. PRIMAXIN® was administered at a dose of 25/25 mg/kg/q6 h for patients aged 3 months to <3 years and at a dose of 15/15 mg/kg/q6 h for patients aged 3 to 12 years.

TABLE 12: MEAN VALUES OF PHARMACOKINETIC PARAMETERS OF IMPENEM/CILASTATIN IN CHILDREN AFTER MULTIPLE DOSES

TOTAL No. PTS	AGE RANGE (yrs)	TOTAL AUC ^{xx} (mcg.h/mL/mg)**	PLASMA CLEARANCE (mL/min/kg)**	VOLUME OF DISTRIBUTION (L/kg)**	RENAL CLEARANCE (mL/min)	T _½ ⁺ (min)	DOSING INTERVAL URINARY RECOVERY (% OF DOSE)
106 [†]	1 ≤ 3	0.18/ ^x (n=1)/-	6.9/ ^x (n=1)/-	0.23/ ^x (n=1)/-	59/ ^x (n=1)/-	67.9/ ^x (n=1)/-	63.5/78.6 (n=1)/(n=1)
	3 ≤ 6	0.08/ ^x (n=1)/-	12.7/ ^x (n=1)/-	0.55/ ^x (n=1)/-	85/ ^x (n=1)/-	60.0/ ^x (n=2)/-	39.4/61.7 (n=1)/(n=1)
	6 ≤ 9	0.10/ ^x (n=1)/-	6.4/ ^x (n=1)/-	0.33/ ^x (n=1)/-	100/ ^x (n=1)/-	54.7/ ^x (n=1)/-	57.0/71.3 (n=1)/(n=1)
	9 ≤ 12	0.07/ ^x (n=3)/-	6.0/ ^x (n=3)/-	0.24/ ^x (n=3)/-	118 to 161/ ^x (n=3)/-	52.3/ ^x (n=3)/-	53.0/65.6 (n=4)/(n=4)
178 [†]	≤ 1	0.42/0.34 (n=10)/(n=3)	5.1/5.3 (n=10)/(n=3)	0.30/0.19 (n=10)/(n=3)	20 to 47/ 37 to 64 (n=6)/(n=3)	58.0/59.0 (n=10)/(n=3)	≥ 44/ ≥ 67 ^{xxx} (n=6)/(n=5)
	1 ≤ 3	0.40/0.41 (n=10)/(n=3)	3.8/4.0 (n=6)/(n=3)	0.14/0.11 (n=6)/(n=3)	32 to 51/ 54 to 57 (n=5)/(n=2)	52.0/41.0 (n=6)/(n=3)	≥ 77/ ≥ 73 ^{xxx} (n=5)/(n=4)
	3 ≤ 6	0.19/0.24 (n=7)/(n=2)	5.2/5.4 (n=7)/(n=2)	0.22/0.13 (n=7)/(n=1)	48 to 99/44 (n=6)/(n=1)	48.0/23.0 (n=7)/(n=2)	≥ 73/ ≥ 51 ^{xxx} (n=6)/(n=5)
	6 ≤ 9	0.14/ ^x (n=7)/-	4.7/ ^x (n=7)/-	0.21/ ^x (n=7)/-	53 to 116/ ^x (n=4)/-	55.0/ ^x (n=7)/-	≥ 63/ ≥ 89 ^{xxx} (n=4)/(n=2)
	9 ≥ 12	0.17/0.22 (n=4)/(n=2)	4.4/4.4 (n=4)/(n=2)	0.22/0.13 (n=4)/(n=2)	28 to 124/ 37 to 87 (n=2)/(n=2)	73.0/39.0 (n=4)/(n=2)	≥ 75/ ≥ 64 ^{xxx} (n=2)/(n=2)

** Geometric means

+ Harmonic means

† Number of patients evaluated pharmacokinetically is indicated in parentheses

x Insufficient data


xx Dosing interval AUC (0-6h) expressed per mg of drug administered

xxx Means not provided

Representative plasma concentration profiles of imipenem and cilastatin at doses of 15/15 and 25/25 mg/kg are shown in Figure 2. In these studies, plasma concentrations of cilastatin were below detectable limits three hours postdosing. Steady state conditions for imipenem and cilastatin prevailed before the end of the fourth dose on Day 1.

Because of the short half-lives of imipenem and cilastatin, no accumulation was observed when PRIMAXIN[®] was given every 6 hours. As in the single dose pediatric studies, the disposition of imipenem and cilastatin resembled that of adults, except for a greater rate of cilastatin elimination.

Imipenem Plasma Concentration



Cilastatin Plasma Concentration




FIGURE 2: Representative Mean Steady-State Plasma Concentrations of Imipenem and Cilastatin in Pediatric Patients Receiving Imipenem/Cilastatin Sodium Every Six Hours

- **Geriatrics** : In 4 female and 2 male healthy volunteers, 65 to 75 years old (mean age 68.8) with normal renal function for their age, i.e., creatinine clearance 84.3 (± 13.0) mL/min/1.73 m² (1.41(± 0.2) mL/s/1.73 m²), PRIMAXIN[®] was administered by intravenous infusion at a dose of 500/500 mg in 100 mL saline over a period of 20 minutes.

The pharmacokinetic parameters for imipenem and cilastatin are summarized in Table 12.

TABLE 13: PHARMACOKINETIC PARAMETERS FOR IMIPENEM AND CILASTATIN IN THE ELDERLY (SINGLE DOSE OF 500/500 mg BY I.V. INFUSION OVER 20 min)

PARAMETER	IMIPENEM		CILASTATIN	
	MEAN (\pm S.D.)	RANGE	MEAN	RANGE
Total urinary recovery (% dose)	58 \pm 7	49 - 66	69 \pm 11	49 - 80
Renal clearance (mL/min)	79 \pm 11	67 - 95	98 \pm 26	64 - 133
Plasma clearance (mL/min)	132 \pm 10	122 - 147	142 \pm 22	117 - 171
Total AUC (mcg . h/mL)	64 \pm 5	57 - 68	60 \pm 9.1	49 - 71
Plasma half-life (min)	90 ⁺	84 - 102	66 ⁺	54 - 96

- ⁺ Harmonic means

No dosage adjustment is necessary for elderly patients whose degree of renal function is normal for their age.

- **Renal Insufficiency**
Impaired Renal Function


PRIMAXIN[®] was administered to six healthy male volunteers and 25 patients with different degrees of renal impairment at a dose of 250/250 mg, in single I.V. infusions over 5 minutes.

The pharmacokinetic parameters for imipenem and cilastatin are summarized in Table 13 and the plasma concentration profiles are shown in Figures 3 and 4 respectively.

TABLE 14: PHARMACOKINETIC PARAMETERS FOR IMIPENEM AND CILASTATIN IN PATIENTS WITH RENAL FAILURE (SINGLE DOSE OF 250/250 mg BY I.V. INFUSION OVER 5 min)

GROUP	No.	No. PTS	CREATININE		RENAL CLEARANCE (mL/min)	PLASMA CLEARANCE (mL/min)	[AUC] ^x (mcg.h/mL)	T1/2 ^{xx} (min)
			MEAN AGE (yrs)	CLEARANCE mL/min/1.73 m ² (mL/s/1.73 m ²)				
IMIPENEM								
I	6	22.8	>100 (>1.7)	46.2	101.9	219.5	19.8	56
II	6	41.8	31-99 (0.52-1.65)	51.0 ^y	77.7 ^y	157.2	30.3	92
III	9	50.8	10-30 (0.17-0.50)	26.1 ^{zz}	24.2 ^{zz}	86.2	51.6	139
IV	2	32&67	<10 (<0.17)	11.3	8.5	69.3	60.6	160
V _a	4	42.3	Hemodialysis [†]			184.0	23.1	74
V _b	4	61.5	Hemodialysis ^{††}	3.4	1.8	59.1	73.1	181
CILASTATIN								
I	6	22.8	>100 (>1.7)	59.4	100.7	168.5	25.4	54
II	6	41.8	31-99 (0.52-1.65)	71.2 ^y	71.3 ^y	99.9	45.7	84
III	9	50.8	10-30 (0.17-0.50)	61.9 ^z	23.9 ^{zz}	38.4	135.3	198
IV	2	32&67	<10 (<0.17)	39.4	6.5	16.2	261.4	462
V _a	4	42.3	Hemodialysis [†]			74.9	56.7	132
V _b	4	61.5	Hemodialysis ^{††}	17.9	2.0	11.4	416.8	696

[†] Received dose during hemodialysis
^{††} Measurements done between dialysis sessions
^x AUC normalised to a 250 mg dose
^{xx} Harmonic means
^y n = 5
^z n = 6
^{zz} n = 8



† Received dose during hemodialysis
 †† Measurements done between dialysis sessions

FIGURE 3: MEAN IMIPENEM PLASMA CONCENTRATIONS FOLLOWING A SINGLE-DOSE OF PRIMAXIN® (250/250 mg I.V., OVER 5 min) TO SUBJECTS WITH VARYING DEGREES OF RENAL INSUFFICIENCY




FIGURE 4: MEAN CILASTATIN PLASMA CONCENTRATIONS FOLLOWING A SINGLE-DOSE OF PRIMAXIN® (250/250 mg I.V., OVER 5 min) TO SUBJECTS WITH VARYING DEGREES OF RENAL INSUFFICIENCY

PRIMAXIN® was administered to 15 hospitalized patients (age range: 39-72 years) with proven or suspected urinary infection, at a dose of 500/500 mg by I.V. infusion over 20 minutes, repeated every 6 hours, for 3 to 10 days.

The pharmacokinetic parameters for imipenem and cilastatin are summarized in Table 14.

Repeated administration did not alter the disposition of either imipenem or cilastatin from that observed after a single dose and steady state prevailed by the end of first day dosing.

TABLE 15: PHARMACOKINETIC PARAMETERS FOR IMIPENEM AND CILASTATIN WHEN PRIMAXIN® WAS ADMINISTERED AT 500/500 mg BY I.V. INFUSION OVER 20 min - EVERY 6 h

GROUP	DOSE	URINARY RECOVERY 0 - 6 h(mg)	RENAL CLEARANCE (mL/min)	PLASMA CLEARANCE (mL/min)	[AUC] 0 - 6 h (mcgmg.h/mL)	T1/2 ^x (min)
IMIPENEM						
I ^a	1st	250.1 (± 45.5) n = 9	105.1 (±39.0) n = 9	201.2 (±63.8) n = 9	42.9 (±10.7) n = 9	80 n = 9
	N th	287.0 (±100.7) n = 8	128.3 (±69.1) n = 8	222.5 (±46.8) n = 8	39.1 (± 8.9) n = 8	72 n = 9
II ^b	1st	183.5 (± 39.8) n = 4	69.3 (±14.0) n = 4	167.0 (±50.9) n = 5	50.7 (±16.8) n = 5	98 n = 5
	N th	231.5 (± 40.3) n = 4	87.8 (±26.2) n = 4	175.7 (±49.5) n = 5	51.0 (±15.9) n = 5	100 n = 5
CILASTATIN						
I ^a	1st	342.1 (± 70.6) n = 3	122.5 (±22.7) n = 3	214.7 (±59.3) n = 9	40.9 (±11.8) n = 9	57 n = 9
	N th	258.7 (± 73.6) n = 3	100.8 (±26.2) n = 3	222.6 (±60.2) n = 8	39.9 (±10.9) n = 8	55 n = 9
II ^b	1st	204.6 n = 1	50.3 n = 1	148.6 (±60.4) n = 6	59.6 (±23.9) n = 6	92 n = 6
	N th	224.9 (± 59.6) n = 2	71.8 (±26.6) n = 2	158.8 (±60.8) n = 6	60.7 (±27.1) n = 6	86 n = 6

^a Group I = glomerular filtration rate ≥ 100 mL/min/1.73 m² (1.667 mL/s/1.73 m²) and N ≥ 16 doses.

^b Group II = glomerular filtration rate ≤ 100 mL/min/1.73 m² (1.667 mL/s/1.73 m²) but ≥ 50 mL/min/1.73 m² (0.834 mL/s/1.73 m²) and N ≥ 15 doses.

^x Harmonic means.

Six hospitalized patients (4 females, 2 males, mean age 52.3) with a glomerular filtration rate of less than 15 mL/min/1.73 m² (0.25 mL/s/1.73 m²) but not requiring hemodialysis, were administered PRIMAXIN® at a dose of 500/500 mg by I.V. infusion over 20 minutes, every 12 hours for nine doses.

The pharmacokinetic parameter estimates are summarized in Table 15.

TABLE 16: PHARMACOKINETIC PARAMETER ESTIMATES IN PATIENTS WITH SEVERELY IMPAIRED RENAL FUNCTION

	DOSE No.	IMIPENEM MEAN	CILASTATIN MEAN
Urinary recovery (% administered dose)	1	15.2	38.0
	9	13.8 (1.2)	46.7 ^x (6.5)
Renal clearance (mL/min)	1	7.8	10.4
	9	7.1 ^x (0.6)	9.1 (1.6)
Plasma clearance (mL/min)	1	51	21
	9	54 ^{xxx} (1.2)	19 (1.9)
12-hour AUC (mcg hr/mL)	1	158	313
	9	159 (4.3)	431 ^{xxx} (33)
Plasma half-life ^a (h)	1	2.9	5.7
	9	2.6 ^{xx}	5.5

^x Different from Dose 1, .05 < p ≤ .10

^{xx} Different from Dose 1, .01 < p ≤ .05

^{xxx} Different from Dose 1, p ≤ .01

^a Inverse (harmonic) transformed data

Numbers in parentheses are within patient standard deviations.

Probenecid

In twelve male volunteers (mean age 29.5, range 23-37) PRIMAXIN[®] was administered at a dose of 500/500 mg with and without probenecid (1 g orally at ten hours and one hour prior to treatment). The urinary recovery of imipenem and cilastatin and their pharmacokinetic data are given in Table 16.

TABLE 17: EFFECT OF PROBENECID ON THE PHARMACOKINETICS AND URINARY RECOVERY OF IMIPENEM AND CILASTATIN WHEN IMIPENEM/CILASTATIN SODIUM (500/500 mg) WAS ADMINISTERED

	IMIPENEM/ CILASTATIN SODIUM	IMIPENEM/CILASTATIN SODIUM PLUS PROBENECID
Imipenem		
Plasma clearance (mL/min)	185 (± 32) ^x	159 (± 24)
AUC (mcg.h/mL)	46 (± 7)	53 (± 8)
Plasma half-life (min) ^{xx}	58	66
Urinary recovery (% dose)	66 (± 3)	55 (± 6)
Renal clearance (mL/min)	125 (± 20)	88 (± 17)
Cilastatin		
Plasma clearance (mL/min)	218 (± 39)	89 (± 10)
AUC (mcg.h/mL)	39 (± 7)	95 (± 11)
Plasma half-life (min) ^{xx}	48	102
Urinary recovery (% dose)	75 (± 6)	75 (± 8)
Renal clearance (mL/min)	173 (± 31)	70 (± 9)

^x Mean (±S.D.)

^{xx} Harmonic means

11 STORAGE, STABILITY AND DISPOSAL

COMPATIBILITY AND STABILITY

List of diluents

- 0.9% Sodium Chloride Injection
- 5% Dextrose Injection
- 5% Dextrose with 0.9% Sodium Chloride Injection
- 5% Dextrose with 0.225% or 0.45% Sodium Chloride Injection

Reconstituted solutions

Reconstituted solutions of PRIMAXIN[®] range from colourless to yellow. Variations of colour within this range do not affect the potency of the product.

PRIMAXIN[®] when reconstituted and diluted with the appropriate diluents as described above, maintains satisfactory potency for **four hours at room temperature and for 24 hours under refrigeration (4°C)** (see [4 DOSAGE AND ADMINISTRATION](#) / [Reconstitution](#)). Do not freeze solutions of PRIMAXIN[®].

STORAGE

The dry powder should be stored at 15°C-30°C.

12 SPECIAL HANDLING INSTRUCTIONS

No special handling instructions are required for this drug product.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance


Proper name: imipenem and cilastatin sodium for injection

Chemical name:

Imipenem

(5*R*,6*S*)-3-[[2-(formimidoylamino)ethyl]thio]-6-[(*R*)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid monohydrate.

Structural Formula:



Molecular Formulae:

$C_{12}H_{17}N_3O_4S \cdot H_2O$

Molecular Weight:


317.37

Description:

Imipenem is an off-white, nonhygroscopic crystalline compound. It is sparingly soluble in water, and slightly soluble in methanol.

Cilastatin sodium

Sodium (*Z*)-7-[[(*R*)-2-amino-2-carboxyethyl]thio]-2-[(*S*)-2,2-dimethylcyclopropane-carboxamido]-2-heptenoate.



$C_{16}H_{25}N_2O_5S Na$

380.43

Cilastatin is an off-white to yellowish-white, hygroscopic, amorphous compound. It is very soluble in water and in methanol.

14 CLINICAL TRIALS

14.1 Clinical Trial by Indication

Clinical trial information is not available.

15 MICROBIOLOGY

Mechanism of action

PRIMAXIN® consists of two components: imipenem and cilastatin sodium in a 1:1 ratio by weight.

Imipenem is a B-lactam carbapenem antibacterial which is also referred to as N-formimidoyl-thienamycin. It is a semi-synthetic derivative of thienamycin, the parent compound produced by the filamentous bacterium *Streptomyces cattleya*.

Imipenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Gram-positive and Gram-negative bacteria through binding to penicillin-binding proteins (PBPs).

Cilastatin sodium is a competitive, reversible and specific inhibitor of dehydropeptidase-I, the renal enzyme which metabolizes and inactivates imipenem. It is devoid of intrinsic antibacterial activity.

Mechanism of resistance

Bacterial resistance to imipenem which has been observed clinically may be due to the following:

- Decreased permeability of the outer membrane of Gram-negative bacteria (due to diminished production of porins)
- Imipenem may be actively removed from the cell with an efflux pump.
- Reduced affinity of PBPs to imipenem
- Imipenem is stable to hydrolysis by most beta-lactamases, including penicillinases and cephalosporinases produced by gram-positive and gram-negative bacteria, with the exception of some carbapenem hydrolysing beta-lactamases known as carbapenemases. Species resistant to other carbapenems do generally express co-resistance to imipenem. There is no target-based cross-resistance between imipenem and agents of the quinolone, aminoglycoside, macrolide and tetracycline classes.

Interaction with Other Antimicrobials

Antagonism by imipenem of the activity of other beta-lactam antibiotics has been observed, *in vitro*, when tested against species of *Enterobacteriaceae* and *Pseudomonas aeruginosa* that contain Type-I chromosomal encoded cephalosporinase. The antagonism results from the reversible induction of the

cephalosporinase by subinhibitory levels of imipenem. The organisms with induced levels of cephalosporinase, however, remain susceptible to imipenem.

Synergistic interaction with other antibiotics such as amino-glycosides has been observed in gram-negative species including *P. aeruginosa* and gram-positive species such as *E. faecalis* and *Nocardia asteroides*.

Spectrum of activity

Imipenem has *in vitro* activity against a wide range of gram-positive and gram-negative organisms. Imipenem has been shown to be active **against most strains** of the following microorganisms both *in vitro* and in clinical infections as described in the [1 INDICATIONS](#) section.

Gram-positive aerobes:

- *Nocardia asteroides*
- *Staphylococcus* (excluding methicillin resistant strains)
- *Streptococcus*

[*Enterococcus faecium* (formerly *Streptococcus faecium*) is not susceptible to PRIMAXIN®.]

Gram-negative aerobes:

- *Acinetobacter* spp.
- *Citrobacter* spp.
- *Enterobacter* spp.
- *Escherichia coli*
- *Haemophilus influenzae*
- *Haemophilus parainfluenzae*
- *Klebsiella* spp.
- *Morganella morganii*
- *Proteus vulgaris*
- *Providencia* spp.
- *Pseudomonas aeruginosa*
- *Serratia marcescens*

Gram-positive anaerobes:

- *Clostridium* spp. (excluding *C. difficile*)
- *Peptococcus* spp.
- *Peptostreptococcus* spp.

Gram-negative anaerobes:

- *Bacteroides* spp., including *B. fragilis*

The following *in vitro* data are available, but their clinical significance is unknown: Imipenem exhibits *in vitro* minimum inhibitory concentrations (MICs) of 4 mcg/mL or less against most ($\geq 90\%$) strains of the following microorganisms; however, the safety and effectiveness of imipenem in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.

Gram-positive aerobes:

- *Bacillus* spp.
- *Listeria monocytogenes*
- *Staphylococcus saprophyticus*
- Group C streptococci
- Group G streptococci
- Viridans group streptococci

Gram-negative aerobes:

- *Aeromonas hydrophila*
- *Alcaligenes* spp.
- *Capnocytophaga* spp.
- *Gardnerella vaginalis*
- *Haemophilus ducreyi*
- *Neisseria gonorrhoeae* including penicillinase-producing strains
- *Pasteurella* spp.
- *Providencia stuartii*

Gram-positive anaerobes:

- *Bifidobacterium* spp.
- *Eubacterium* spp.
- *Propionibacterium* spp.

Gram-negative anaerobes:

- *Fusobacterium* spp.
- *Prevotella bivia*
- *Prevotella disiens*
- *Prevotella melaninogenica*
- *Veillonella* spp.

Stenotrophomonas maltophilia (formerly *Xanthomonas maltophilia*, formerly *Pseudomonas maltophilia*), *Burkholderia cepacia*-complex (formerly *Pseudomonas cepacia*), Methicillin-resistant *S. aureus* and *S. epidermidis*, *Enterococcus faecium* (formerly *Streptococcus faecium*), *Flavobacterium* spp., *Corynebacterium* (J.K.), *Fusobacterium varium*, and species of *Mycobacterium* and *Chlamydia* are species generally reported insensitive to imipenem.

Susceptibility Testing

Bacterial susceptibility to imipenem is conducted via standardized methods. Dilution and diffusion techniques are used for aerobes and dilution techniques only for anaerobes.

Dilution Techniques

Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of imipenem powder. The MIC values should be interpreted according to criteria and methods provided in Table 17.

Diffusion Techniques

Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 10 mcg imipenem to test the susceptibility of microorganisms to imipenem. The disk diffusion interpretive criteria and methods are provided in Table 17.

Pathogen ^a	Dilution Test (Minimum Inhibitory Concentrations MIC in mcg/mL)			Disk Diffusion Test (Zone Diameters in mm)		
	S	I	R	S	I	R
<i>Enterobacterales^d</i>	≤1.0	2.0	≥4.0	≥23	20-22	≤19
<i>Pseudomonas aeruginosa</i>	≤2	4	≥8	≥19	16-18	≤15
<i>Acinetobacter</i> spp.	≤2	4	≥8	≥22	19-21	≤18
<i>Staphylococcus</i> spp.	Inferred from cefoxitin susceptibility					

<i>Haemophilus influenzae</i> and <i>H. parainfluenzae</i> ^c	≤0.5	-	-	≥19	-	-
<i>Streptococcus pneumoniae</i> ^b	≤0.12	0.25-0.5	≥1	-	-	-
Anaerobes ^b	≤4.0	8.0	≥16.0	-	-	-

^areference is made to those pathogens listed in INDICATIONS section of product monograph; broth and agar dilution methods apply to aerobes other than *Haemophilus* spp. and *Streptococcus pneumoniae* for which only broth dilution applies; the numbers presented for anaerobes reference agar dilution; a hyphen indicates Not Applicable; for further details and applicable laboratory methods see CLSI (Clinical and Laboratory Standards Institute) documents: M7-A7: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically (Jan 2006); M11-A7: Methods for antimicrobial susceptibility testing for anaerobic bacteria (Jan 2007); M100-S24: Performance standards for antimicrobial susceptibility testing (Jan 2014)

^b Agar dilution there are no CLSI interpretive criteria for MIC testing of beta hemolytic *Streptococcus* spp. or *viridans* group Streptococci against imipenem (ref CLSI ref M100-S24, table 2 H1 and table 2 H2);

^c absence of data on resistant strains precludes defining any other category than ‘susceptible’ (see CLSI document M100–S24, table 2E)

^d Imipenem MICs for *Proteus* spp., *Providencia* spp., and *Morganella morganii* tend to be higher (e.g., MICs in the intermediate or resistant range) than meropenem or doripenem MICs. These isolates may have elevated MICs by mechanisms other than the production of carbapenemases. (CLSI M100-ED 31 2021)

A report of “Susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial compound in blood reaches the concentrations usually achievable. A report of “Intermediate” indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.

Quality Control

Standardized susceptibility test procedures require the use of quality control microorganisms to control the technical aspects of the test procedures. Standard imipenem powder as used in the dilution test and 10 mcg imipenem impregnated discs as used in the diffusion test should provide the following range of values noted in Table 18.

TABLE 19: ACCEPTABLE QUALITY CONTROL ORGANISMS and TEST RANGES for IMIPENEM

QC Strain	ATCC ^{® a}	Dilution Test (MICs in mcg/mL)	Disk Diffusion Test (zone diameters in mm)
<i>Enterococcus faecalis</i> ^b	29212	0.5-2	Not Applicable
<i>Staphylococcus aureus</i> ^b	29213	0.015-0.06	Not Applicable
<i>Streptococcus pneumoniae</i> ^c	49619	0.03-0.12	Not Applicable
<i>Escherichia coli</i> ^b	25922	0.06-0.25	26-32
<i>Haemophilus influenzae</i> ^c	49766	0.25-1	Not Applicable
<i>Haemophilus influenzae</i> ^c	49247	Not Applicable	21-29
<i>Pseudomonas aeruginosa</i> ^b	27853	1-4	20-28
<i>Bacteroides fragilis</i> ^d	25285	0.03-0.125	Not Applicable
<i>Bacteroides thetaiotaomicron</i> ^d	29741	0.125-0.5	Not Applicable
<i>Eubacterium lentum</i> ^d	43055	0.125-0.5	Not Applicable
<i>Klebsiella pneumoniae</i> ^e	700603	0.03-0.25	Not Applicable
<i>Klebsiella pneumoniae</i> ^e	BAA-1705	4-16	Not Applicable
<i>Klebsiella pneumoniae</i> ^e	BAA-2814	16-64	Not Applicable

^a ATCC[®] is the registered trademark of the American Type Culture Collection.

^b reference CLSI document M100-S24 (broth dilution table 5A ; disk diffusion table 4A)

^c reference CLSI document M100-S24 (broth dilution table 5B ; disk diffusion table 4B)

^d reference CLSI document M11-A7 (agar dilution table 5D)

^e reference CLSI document M100-Ed31 (table 5A-2)

16 NON-CLINICAL TOXICOLOGY

Animal pharmacology

Central Nervous System

Imipenem: In female mice (5 per dose level) imipenem at doses of 6, 30 and 150 mg/kg, I.P. showed no effect on behavior or in various pharmacological tests of central nervous system activity.

In male rats (11 per dose level) imipenem at doses up to 100 mg/kg, I.V. showed no effect on spontaneous locomotor activity and had no effect on the neuromuscular junction.

No behavioral or overt signs of central nervous system activity were observed when imipenem was given to squirrel monkeys at cumulative oral doses of 1, 3 and 9 mg/kg given at 90 minute intervals (0, 90 and 180 minutes) in an avoidance response test.

The effects of imipenem on the electrocardiogram (ECG), spontaneous electroencephalogram (EEG) and the EEG arousal response in rabbits immobilized by gallamine were studied. ECG and EEG were recorded for 60 minutes following drug administration. A single dose of 50 mg/kg, I.V. of imipenem (5 animals) had no effect on either the ECG or EEG. A single I.V. dose of 200 mg/kg, (6 animals) increased the threshold voltage for EEG arousal response significantly ($22.9 \pm 9.5\%$) only at 45 minutes.

Cilastatin Sodium: Cilastatin sodium was studied in mice in the same pharmacological tests of CNS activity as used for imipenem at doses of 6, 30 and 150 mg/kg, I.P. With the exception of a possible antagonism of neurotensin hypothermia in 2 out of 5 mice given 30 mg/kg, I.P., no effects were observed.

In rats at doses up to 100 mg/kg, I.V. cilastatin sodium showed no effect on spontaneous locomotor activity and had no effect on the neuromuscular junction.

In squirrel monkeys trained on a continuous avoidance schedule, avoidance response was unaltered by cilastatin sodium at cumulative oral doses of 5, 10 and 20 mg/kg administered at 90 minutes intervals (0, 90 and 180 minutes).

Imipenem/Cilastatin Sodium: Imipenem/cilastatin sodium at doses of 25/25 and 100/100 mg/kg, I.V. induced no significant effect on central or autonomic nervous system activities in conscious mice.

The anticonvulsant activity of imipenem/cilastatin sodium was evaluated in mice on convulsions induced by electroshock, strychnine or pentylenetetrazol. At doses up to 100/100 mg/kg, I.V. no anticonvulsant effect was observed.

Imipenem/cilastatin sodium at doses up to 100/100 mg/kg, I.V. had no effect on spontaneous locomotor activity in rats. Imipenem/cilastatin sodium at doses up to 100/100 mg/kg, I.V. had no effect on the neuromuscular junction in rats (as measured by the contractile response of the gastrocnemius muscle to electrical stimulation of the peroneal nerve).

Imipenem alone, cilastatin sodium alone and the combination (1:1 ratio) were administered intravenously to male rabbits at dosage levels of 50, 100 and 200 mg/kg to study the effect on the spontaneous electroencephalogram (EEG). Cefazolin was administered as a comparative agent at doses of 200, 400 or 1000 mg/kg. At 200 mg/kg imipenem alone caused seizure discharge in 1 of 11 rabbits 27 minutes after drug administration. This seizure discharge did not continue, but appeared again at 45 and 61 minutes. No effect on the spontaneous EEG activity was observed in the remaining 10 animals receiving 200 mg/kg of imipenem. Cilastatin had no effect on the EEG. Among rabbits receiving imipenem/cilastatin sodium at 200/200 mg/kg (the highest dose given), seizure discharge was observed in 2 of 11 rabbits from 15 minutes to 58 minutes after drug administration. Seizure discharge was observed with cefazolin at a dosage level of 400 mg/kg in 2 of 5 rabbits from 13 to 60 minutes after injection. Electrical disturbance of EEG activity was observed in all rabbits receiving cefazolin at 1000 mg/kg.

When tested in rat hippocampal slices *in vitro*, the GABA receptor blocking activity of imipenem was comparable to that seen with cefazolin. The GABA receptor blocking activity of imipenem/cilastatin sodium was somewhat less than that of imipenem alone. Cilastatin sodium alone had some antagonistic effect although it was significantly less than that observed with imipenem and other reference beta-lactam antibiotics.

In vivo studies in rats have shown that imipenem is convulsive after direct application of the drug into the cisterna magna. Coadministration of cilastatin sodium and imipenem in this model showed no differences in the convulsant potential compared to imipenem alone. Although direct introduction of imipenem into the rat brain is capable of producing convulsant activity, no evidence of such activity was observed in rats receiving imipenem alone at dosage levels up to 180 mg/kg/day S.C., once daily, for 6 months or with imipenem/cilastatin sodium at dosage levels up to 320/320 mg/kg/day S.C., once daily, for 6 months. In addition, no evidence of convulsant activity was observed in rhesus monkeys receiving imipenem alone, at doses up to 180 mg/kg/day I.V., once daily, for 5 weeks or imipenem/cilastatin sodium at dosage levels up to 180/180 mg/kg/day S.C., once daily, for 6 months.

Imipenem, cilastatin sodium, and the 1:1 combination were evaluated in male rabbits at dosage levels of 50 and 100 mg/kg, I.V. for their effect on the EEG arousal response. At a dosage level of 200 mg/kg, imipenem alone increased the threshold voltage by approximately 23% at 45 minutes after drug administration. Cilastatin sodium at 50 mg/kg produced a slight but statistically significant decrease in the threshold voltage for EEG arousal response. A similar slight decrease in threshold voltage was noted

for the combination at a dose of 200/200 mg/kg. The reference compound for this study (diazepam, 5 mg/kg) increased the threshold voltage by 87% at 15 minutes and by 70% at 60 minutes.

Cardiovascular and Respiratory System

Imipenem: Imipenem did not significantly lower blood pressure at 20 mg/kg, I.P. in spontaneously hypertensive rats, although a slight transient increase (11%) in mean arterial blood pressure was observed two hours after treatment.

In groups of 3 dogs anesthetized with sodium pentobarbital, imipenem given intravenously at doses of 25 mg/kg and 100 mg/kg had no effect on heart rate, arterial blood pressure, respiratory rate or ECG. In one dog (dosed at 100 mg/kg) heart rate increased by about 25 beats/min (21%) and systolic blood pressure increased about 16 mmHg (12%). In respiratory studies in dogs anesthetized with thiopental, imipenem at doses of 2.5 and 10 mg/kg, I.V. had no effect on the respiratory parameters measured (total lung resistance, dynamic lung compliance, tidal volume and respiratory rate).

Cilastatin Sodium: No appreciable change in basal blood pressure or heart rate was observed in spontaneously hypertensive rats or dogs dosed with cilastatin sodium at 10 mg/kg, I.V.

Cilastatin sodium at doses up to 100 mg/kg, I.V. did not change blood pressure, heart rate, respiratory rate and ECG in dogs anesthetized with sodium pentobarbital.

Imipenem/cilastatin sodium: At doses of 25/25 and 100/100 mg/kg, I.V. imipenem/cilastatin sodium significantly ($p < 0.05$) inhibited the carotid sinus reflexes (24.5% and 36% respectively) in dogs anesthetized with sodium pentobarbital.

In other studies in dogs anesthetized with sodium pentobarbital, a dose of imipenem/cilastatin sodium 100/100 mg/kg, I.V. decreased mean blood pressure (7 to 13 mmHg) within 4 to 15 minutes after the start of drug infusion, without any significant change in heart rate and respiration rate. This may have been related to the inhibition of the carotid sinus reflexes observed in the previous study. A dose of 25/25 mg/kg, I.V. did not affect these parameters.

Other Systems

Imipenem: In mice (male, 8 per dosage level), imipenem administered subcutaneously at doses of 2.5 to 20 mg/kg or intravenously at doses of 25 and 100 mg/kg had no effect on the intestinal propulsion rate.

No diuretic activity was observed in rats given imipenem at doses up to 10 mg/kg, I.P. or in dogs given 5 mg/kg, I.V.

In seven female dogs, gastric secretion evoked by gastrin tetrapeptide resulted in total acid output at the 0- to 30-minute collection which was significantly reduced (59%, $p < 0.05$) following an oral dose of imipenem of 20 mg/kg. This was related to a reduction in output volume. The integrated 0- to 90-minute total acid output and output volume did not differ significantly ($p > 0.05$) from those in a placebo trial in the same animals. Acid concentration was not affected by imipenem. Basal gastric secretion in dogs was not affected following oral doses of 10 or 20 mg/kg of imipenem.

Cilastatin Sodium: In pylorus-ligated rats, cilastatin sodium (25 and 100 mg/kg, I.V.) showed no effect on basal gastric output, acid output, pH and pepsin output.

Cilastatin sodium (25 and 100 mg/kg, I.V.) showed no effect on intestinal propulsion in male mice.

Cilastatin sodium (10 mg/kg, I.V.) did not substantially change urinary Na^+ , K^+ or Ca^{++} excretion in beagle dogs.

In female dogs, cilastatin sodium (10 mg/kg, I.V.) did not significantly alter the response to gastrin tetrapeptide. Basal gastric output was reduced but not to a statistically significant degree.

Imipenem/cilastatin sodium: Imipenem/cilastatin sodium at doses of 25/25 and 100/100 mg/kg, I.V. had no effect on basal gastric secretion in pylorus-ligated rats. In mice, imipenem/cilastatin sodium (25/25 and 100/100 mg/kg, I.V.) had no effect on intestinal propulsion.

Acute Toxicity

	LD ₅₀	
	RAT	MOUSE
Imipenem I.V.	>2000 mg/kg	≅1500 mg/kg
Cilastatin Sodium I.V.	≅5000 mg/kg	≅8709 mg/kg
PRIMAXIN® I.V.	≅1000 mg/kg	≅1100 mg/kg

Subacute and Chronic Toxicity

Imipenem: The principal studies used to evaluate the subacute and chronic toxicity of the product are shown in Table 19.

Animal studies showed that the toxicity produced by imipenem as a single entity, was limited to the kidney. Nephrotoxicity (characterized by proximal tubular necrosis) was observed in rabbits and monkeys receiving high doses of imipenem (150 mg/kg, I.V. and 180 mg/kg, I.V. respectively); the rabbit is more sensitive to the nephrotoxic effect of imipenem than is the monkey. No adverse effects were

observed after 6 months of administration of imipenem in rats (25 males and 25 females per dosage level), at dosage levels up to 180 mg/kg/day, or in monkeys (5 males and 5 females per dosage level) at dosage levels up to 120 mg/kg/day.

TABLE 20: PRINCIPAL SUBACUTE AND CHRONIC TOXICITY STUDIES WITH PRIMAXIN®¹

Duration	Species, Number/Sex/Group	Dosage Levels (mg/kg/day)	No Adverse Effect Level (mg/kg/day)	Principal Effects Observed
Studies with Imipenem Alone				
5-Week, I.V.	Rat, 15	20, 60, 180	180	No adverse effects observed.
5-Week, I.V.	Monkey, 3M, 3F	20, 60, 180	60	1/6 dead with renal tubular necrosis at 180; an additional death from unknown cause at 180 presumed related to injection of highly concentrated drug solution necessitated by dosage level.
6-Month, I.V. (w/3-mo interim necropsy)	Rat, 25 (10 for interim necropsy)	20, 60, 180	180	Increased rate of weight gain in males at 60 and 180; no adverse effects seen.
6-Month, I.V. S.C. (w/3-mo interim necropsy)	Monkey, 5 (2 for interim necropsy)	30, 60 I.V. 120 S.C.	120	No adverse systemic effects seen.
Studies with Cilastatin Alone				
5-Week, I.V.	Rat, 15	20, 100, 500	500	No adverse effects seen.
5-Week, S.C.	Rat, 15	500, 1250, 3125	500	Renal tubular vacuolation seen at 1250 and 3125.
5-Week, I.V.	Monkey, 3	20, 100, 500	500	No drug-induced adverse effects.
14-Week, I.V.	Rat, 15	20, 100, 500	500	No changes related to treatment.

¹Although many studies in addition to those listed here were conducted, this list presents the principal studies which formed the basis of the safety evaluation of this drug.

TABLE 20: PRINCIPAL SUBACUTE AND CHRONIC TOXICITY STUDIES WITH PRIMAXIN® (continued)

Duration	Species,Number/Sex/Group	Dosage Levels (mg/kg/day)	No Adverse Effect Level(mg/kg/day)	Principal Effects Observed
Studies with Imipenem and Cilastatin Sodium in Combination (PRIMAXIN®)				
5-Week, I.V., S.C.	Rat, 15	20/20, 80/80 I.V. 320/320 S.C.	320/320	No drug-induced adverse effects.
5-Week, I.V., S.C.	Monkey, 3	20/20, 60/60 I.V. 180/180 S.C.	180/180	No changes related to treatment.
14-Week, I.V., S.C.	Rat, 15	20/20, 80/80, 320/320	320/320	No changes related to treatment.
14-Week, S.C.	Infant Monkey, 3	20/20, 60/60 180/180	180/180	No adverse drug-induced changes.
10-Week, S.C.	Newborn Monkey, 5M, 3F	180/180	180/180	No drug-induced adverse effects.
6-Month, I.V., S.C.	Rat, 30	20/20, 80/80 I.V. 320/320 S.C.	320/320	No adverse effects observed.
6-Month, I.V., S.C.	Monkey, 4	20/20, 60/60 I.V. 180/180 S.C.	180/180	No adverse effects observed.

Cilastatin Sodium: No adverse effects were noted after intravenous administration of cilastatin sodium to rats (15 males and 15 females per dosage level) at doses up to 500 mg/kg for 14 weeks and monkeys (3 males and 3 females per dosage level) at doses up to 500 mg/kg for five weeks. In rats (15 males and 15 females per dosage level) given cilastatin sodium at dosages of 1250 or 3125 mg/kg/day, subcutaneously, very slight to slight proximal renal tubular degeneration was observed. After 5 weeks on these doses, no tubular necrosis was found, and there were no changes in any other tissues. Renal function remained normal.

Imipenem/Cilastatin Sodium: Co-administration of cilastatin sodium with imipenem in a 1:1 ratio prevented the nephrotoxic effects of imipenem in rabbits and monkeys, even when the dose of imipenem was 360 mg/kg or 180 mg/kg/day, respectively. These dosage levels are nephrotoxic when administered without cilastatin. This protective effect was seen in the monkey through 6 months of co-administration.

A series of studies performed in rabbits demonstrated that cilastatin sodium prevents the nephrotoxicity of imipenem in animals by preventing its entry into the tubular cells; this action is apparently distinct from the inhibition by administration of dehydropeptidase-I.

Genotoxicity: No evidence of drug-induced genetic toxicity was seen in the tests performed with imipenem or cilastatin sodium; these tests are listed in Table 20.

TABLE 21: PRINCIPAL GENETIC TOXICITY STUDIES WITH PRIMAXIN®

Type of Study	Species, Number/Sex/Group	Dosage Levels(mg/kg/day)	Principal Effects Observed
Studies with Imipenem Alone			
Mutagenic	V-79 cells	3, 10, 20, 36 mM final concentration in medium	No evidence of mutagenic activity
Studies with Cilastatin Sodium Alone			
Mutagenic	Microbial Mutagenesis (<i>S. typhimurium</i>)	With and without S-9:** 30, 100, 300, 1000, 2,000 mcg/plate	Negative
Studies with Imipenem and Cilastatin Sodium in Combination (PRIMAXIN®)			
Mutagenic	V-79 cells	With S-9: 1,3,4,5,7,9,11 mM Without S-9: 3,5,10,15 mM	No mutagenic activity detected
Mutagenic	Unscheduled DNA synthesis, Rat hepatocytes	3,10,14,22 mM final concentration in medium	No increase in labelled nuclei
Mutagenic	<i>In vivo</i> cytogenetic mouse bone marrow	59, 197, 590 mg/kg	No chromosomal aberration seen
Mutagenic	<i>In vitro</i> cytogenetic	With and without S-9: 0.2,	Increased incidence of sister chromatid

	(range-finding)	0.67, 2.0, 6.7, 20 mM and 2.0, 6.7, 20.0, 67 µM	exchanges; study repeated and <i>in vitro</i> and <i>in vivo</i> sister chromatid exchange studies performed (below).
Mutagenic	<i>In vitro</i> chromosomal aberration assay	With S-9: 8.5, 6.4, 4.2, 2.1, 1.1 mM; Without S-9: 21.2 1.2, 17.0, 12.7, 8.5, 4.2 mM	Negative

** Rat liver microsomal activation system

Reproductive and Developmental Toxicology: The principal studies performed to evaluate the effect of imipenem or cilastatin sodium alone or in combination on reproductive parameters or fetal development are shown in Table 21 .

Fertility

The effect of imipenem/cilastatin sodium on fertility was assessed in male and female rats administered doses up to 320/320 mg/kg/day. Drug was administered to males for 12 weeks prior to mating and throughout the mating period. Females received drug beginning 15 days prior to mating, during mating and through Day 19 of gestation.

The only effect of imipenem/cilastatin sodium in these studies was a very slight but statistically significant embryotoxicity and/or fetotoxicity. This was expressed as an increase in the resorption rate among animals receiving 80/80 and 320/320 mg/kg/day as well as a decrease in the number of live fetuses per pregnant female at 20/20 and 80/80 mg/kg/day. No decrease in the number of live fetuses per pregnant female was observed at the highest dosage level and the number of live pups per pregnant female on Day 1 postpartum in all dosage groups were comparable to the control group. The incidence of incompletely ossified sternebra was slightly increased in the 320/320 mg/kg/day group compared to the controls. Although these effects are subtle in nature and small in magnitude, they suggest a slight embryotoxic effect of imipenem/cilastatin sodium at high dosage levels in the rat.

TABLE 22: PRINCIPAL REPRODUCTIVE TOXICITY STUDIES WITH PRIMAXIN^{®1}

Type of Study	Species, Number/Sex/Group	Dosage Levels (mg/kg/day)	Principal Effects Observed
Studies with Imipenem Alone			
Teratology, I.V.	Rat, 23	100, 300, 900	No evidence of fetal malformations; no effect postnatal growth and Behavior
Teratology, I.V.	Rabbit, 20	10, 30, 60	No teratogenic effect.
Studies with Cilastatin Sodium Alone			
Teratology, I.V./S.C.	Rat, 25	40, 200, 1000	No teratogenic effect.
Teratology, I.V./S.C.	Rabbit, 10	30, 100, 300	No teratogenic effect.
Studies with Imipenem and Cilastatin Sodium in Combination (PRIMAXIN[®])			
Fertility, I.V./S.C.. (w/o post- weanling exam)	Rat: 15 male, 30 female	20/20, 80/80, 320/320	No evidence of adverse effect on fertility (slight decrease in live fetal weight at 320/320).
Teratology, I.V.	Mouse, 25	20/20, 80/80, 320/320	No teratogenic effect
Teratology, I.V./S.C. (with post- natal exam)	Rat, 35	20/20, 80/80, 320/320	No teratogenic effect, no adverse effect postnatal growth or behavior.
Late Gestation and Lactation I.V./S.C	Rat, 20	20/20, 80/80, 320/320	No adverse effects observed.
Teratology, I.V./S.C.	Cynomolgus Monkey, 11 (I.V.), 14 (S.C.)	I.V.: 40/40 S.C.: 160/160	Emesis, body weight loss, deaths, abortions at both dose levels; histologic examination of tissues showed no cause of death. No evidence of teratogenicity
Teratology by Infusion 45 (total)	Cynomolgus Monkey	100/100 (Days 21-30; 31-40; 41-50).	Drugs infused daily at 3 mg/mL for 10-day periods No apparent relationship between drug-induced toxicity (emesis) and embryotoxicity.

¹Although several additional studies were performed to evaluate various aspects of reproduction, the studies presented form the basis of the safety evaluation of PRIMAXIN[®].

Teratology

No evidence of a teratogenic effect was observed in rats or rabbits receiving imipenem or cilastatin sodium alone or in combination. Imipenem alone was evaluated at dosage levels up to 900 mg/kg/day, cilastatin sodium alone at dosage levels up to 1000 mg/kg/day and the two drugs in combination at dosage levels up to 320/320 mg/kg/day in rats.

The characteristic intolerance of rabbits to cephalosporin antibiotics was demonstrated in a teratology study with imipenem alone in this species at a dosage level up to 60 mg/kg/day. Maternotoxicity and fetotoxicity were observed at 60 mg/kg/day. The embryo- and fetotoxicity is considered to be secondary to the excess maternotoxicity observed in these studies. In the presence of these effects, there was still no evidence of teratogenicity. No evidence of a teratogenic effect was observed in rabbits receiving cilastatin sodium alone at doses up to 300 mg/kg/day.

Monkeys: In a range-finding study imipenem/cilastatin sodium was administered daily by bolus intravenous injection to non-pregnant cynomolgus monkeys for 30 days at doses of 20/20, 60/60, and 120/120 mg/kg/day (4 females per group) in order to establish dosage levels for subsequent studies. Four additional non-pregnant female monkeys were treated with 180/180 mg/kg/day subcutaneously for 30 days and a control group of 4 monkeys were treated intravenously with 0.9% sodium chloride. Emesis or diarrhea were seen on one or two occasions during treatment in some monkeys in the 60/60 and 120/120 mg/kg/day groups. Three animals in the 180/180 mg/kg/day subcutaneous group had occasional diarrhea during treatment.

In a teratology study, a bolus intravenous dose of 40/40 mg/kg/day and a subcutaneous dose of 160/160 mg/kg/day were administered to pregnant cynomolgus monkeys on Days 20 to 50 of gestation (11 and 14 monkeys per group, respectively). A control group of 14 pregnant monkeys were treated with 0.9% sodium chloride I.V. Both doses of imipenem/cilastatin sodium were maternotoxic and resulted in deaths, reduced appetite, body weight loss, diarrhea, and emesis. In the 40/40 and 160/160 mg/kg/day groups, 7 of 11 and 5 of 14 monkeys lost their embryos. This is considered to reflect the obvious maternotoxicity evident at these dosage levels. There was no evidence of a teratogenic effect in surviving fetuses.

A study was conducted to determine the disposition and metabolism of imipenem/cilastatin sodium in pregnant and non-pregnant cynomolgus monkeys (4-5 monkeys per group). A bolus intravenous dose of 100/100 mg/kg/day was administered for 10 days and the first and last dose contained radioactive imipenem. The data suggest that metabolism or disposition is not directly responsible for the increased sensitivity of pregnant monkeys to imipenem/cilastatin sodium-induced toxicity.

In a teratology study in cynomolgus monkeys, imipenem/cilastatin sodium (100/100 mg/kg/day) was administered to 10 pregnant monkeys per group by slow infusion for 3 consecutive 10-day periods (Days 21-30; 31-40; 41-50). Three groups of 5 pregnant monkeys each were similarly treated with the vehicle. Pregnancy was confirmed by tests for macaque chorionic gonadotropin and the maintenance of pregnancy was assessed through periodic ultrasound examinations. Prior to parturition the fetuses were delivered by cesarean section and examined for malformations. Although there was no evidence of fetal external, visceral or skeletal malformations, there was an increase in the incidence of embryonic/fetal loss in the drug-treated monkeys (7 of 30, 23%) compared to the controls (0 of 15, 0%). Maternotoxicity (emesis and/or gagging during or after treatment) was observed in 4 of the 7 monkeys with embryonic/fetal loss.

Gestation and Postnatal Development

The effect of imipenem/cilastatin sodium during gestation and the postnatal period was studied in rats at doses up to 320/320 mg/kg/day. Imipenem/cilastatin sodium had no effect on growth or survival of offspring.

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PRIMAXIN®

imipenem and cilastatin sodium for injection

Read this carefully before you start taking PRIMAXIN® and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about PRIMAXIN®.

Serious Warnings and Precautions

- **Serious allergic reactions sometimes causing death have happened in patients taking similar medicines like PRIMAXIN® and can also occur with PRIMAXIN®.**
- **Before starting therapy with PRIMAXIN®, tell your doctor about any allergic reactions you have had in the past to other antibiotics or to any other medicines.**
- **If an allergic reaction to PRIMAXIN® occurs, stop taking the medicine and consult your doctor right away. See Serious side effects and what to do about them, below.**

What is PRIMAXIN® used for?

Your physician has prescribed PRIMAXIN® to treat one of the following infections:

- Lung Infections.
- Infections of your urinary tract.
- Infections of your abdomen.
- Infections of the female reproductive system.
- Infection of your blood.
- Infection of your heart called endocarditis caused by a bacterial strain called *Staphylococcus aureus*.
- Infections of your bones and joints.
- Skin Infections.

Antibacterial drugs like PRIMAXIN® treat only bacterial infections. They do not treat viral infections. Although you may feel better early in treatment, PRIMAXIN® should be used exactly as directed. Misuse or overuse of PRIMAXIN® could lead to the growth of bacteria that will not be killed by PRIMAXIN® (resistance). This means that PRIMAXIN® may not work for you in the future.

How does PRIMAXIN® work?

PRIMAXIN® is an antibiotic. It is used to kill a wide range of bacteria that cause infections.

What are the ingredients in PRIMAXIN®?

Medicinal ingredients: imipenem and cilastatin sodium.

Non-medicinal ingredients: sodium bicarbonate.

PRIMAXIN® comes in the following dosage forms:

Sterile powder for solution, 500 mg imipenem and 500 mg cilastatin (as cilastatin sodium) per vial

Do not use PRIMAXIN® if:

- You or your child are allergic to any of its ingredients (see **What are the ingredients in PRIMAXIN®**).

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take PRIMAXIN®. Talk about any health conditions or problems you may have, including if you:

- allergies to any drugs, including beta-lactam antibiotics such as penicillins, or cephalosporins or any other class of antibiotics.
- colitis or any other gastrointestinal (stomach or bowel) disease.
- any central nervous system disorders, such as localized tremors, brain lesions or seizures.
- kidney or urinary problems.

Other warnings you should know about:

Use in Pregnancy and Breast-feeding

Use in Pregnancy

PRIMAXIN® is not generally recommended in pregnant women. You should tell your doctor if you think you are pregnant or plan to become pregnant.

Use in Breast-feeding

PRIMAXIN® is secreted in human milk. As the breast-fed baby may be affected, women who are receiving PRIMAXIN® should not breast-feed. If you intend to breast-feed, talk to your doctor.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with PRIMAXIN®:

- ganciclovir - used to treat some viral infections.
- valproic acid - used to treat epilepsy, bipolar disorder, migraine, or schizophrenia.

Your doctor will decide whether you should use PRIMAXIN® in combination with these medicines.

How to take PRIMAXIN®:

- PRIMAXIN® will be injected into a vein (intravenous injection). PRIMAXIN® must not be taken by mouth.

Usual dose:

PRIMAXIN® will be given to you by a physician or another health care professional who will determine the most appropriate method and dose. The number, type of injection and amount in each injection that you require will depend upon your condition, the severity of your infection as well as the overall health of your kidneys.

It is very important that you continue to receive PRIMAXIN® for as long as your doctor prescribes it.

Your doctor will let you know when you may stop receiving PRIMAXIN®.

Overdose:

If you think you, or a person you are caring for, have taken too much PRIMAXIN®, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed Dose:

The injection schedule will be set by your doctor, who will monitor your response and condition to determine what treatment is needed. However, if you are concerned that you may have missed a dose, contact your doctor or another healthcare professional immediately.

What are possible side effects from using PRIMAXIN®?

These are not all the possible side effects you or your child may have when taking PRIMAXIN®. If you or your child experience any side effects not listed here, tell your healthcare professional.

Common side effects of PRIMAXIN®:

- nausea
- vomiting
- skin redness and tenderness at the injection site or along a blood vessel in the area

Uncommon side effects of PRIMAXIN®:

- hives
- rash
- skin itchiness
- fever
- dizziness
- sleepiness
- low blood pressure

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
Children			
COMMON			
diarrhea		✓	
Adults			
UNCOMMON			
seizures			✓
<i>Clostridium colitis</i> (inflammation of the colon caused by a bacteria) <i>Clostridium</i>)			✓
Adults or children			

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
<p>UNCOMMON Serious hypersensitivity and allergic reactions, occasionally fatal, with symptoms such as severe rash with or without high fever, with itching or hives on the skin, swelling of the face, lips, tongue or other parts of the body, shortness of breath, wheezing or trouble breathing</p>			✓
<p>UNKNOWN Severe Cutaneous Adverse Reactions (SCAR): severe skin reactions that may also affect other organs:</p> <ul style="list-style-type: none"> • Skin peeling, scaling, or blistering (with or without pus) which may also affect your eyes, mouth, nose or genitals, itching, severe rash, bumps under the skin, skin pain, skin color changes (redness, yellowing, purplish) • Swelling and redness of eyes or face • Flu-like feeling, fever, chills, body aches, swollen glands, cough • Shortness of breath, chest pain or discomfort 			✓

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store the dry powder at room temperature between 15-30°C.

Keep out of reach and sight of children.

If you want more information about PRIMAXIN®:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>; the manufacturer's website www.merck.ca, or by calling 1-800-567-2594.

This leaflet was prepared by Merck Canada Inc.

Last Revised DEC 21, 2021

® Merck Sharp & Dohme Corp. Used under license.

© 2011, 2021 Merck Canada Inc. All rights reserved.

* All other trademarks are the property of their respective owner(s).